Relay Therapeutics Net Income vs. Gross Profit
| RLAY Stock | USD 4.80 0.04 0.84% |
Net Loss | First Reported 2019-03-31 | Previous Quarter -92.2 M | Current Value -88.1 M | Quarterly Volatility 44.4 M |
For Relay Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Relay Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Relay Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Relay Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Relay Therapeutics over time as well as its relative position and ranking within its peers.
Relay |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relay Therapeutics. If investors know Relay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relay Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Revenue Per Share 0.076 | Quarterly Revenue Growth 43.279 | Return On Assets (0.27) | Return On Equity (0.43) |
The market value of Relay Therapeutics is measured differently than its book value, which is the value of Relay that is recorded on the company's balance sheet. Investors also form their own opinion of Relay Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relay Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relay Therapeutics' market value can be influenced by many factors that don't directly affect Relay Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relay Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relay Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relay Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Relay Therapeutics Gross Profit vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Relay Therapeutics's current stock value. Our valuation model uses many indicators to compare Relay Therapeutics value to that of its competitors to determine the firm's financial worth. Relay Therapeutics is rated below average in net income category among its peers. It is rated below average in gross profit category among its peers . Relay Therapeutics reported Net Loss of (341.97 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Relay Therapeutics' earnings, one of the primary drivers of an investment's value.Relay Gross Profit vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Relay Therapeutics |
| = | (341.97 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Relay Therapeutics |
| = | 1.38 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Relay Gross Profit Comparison
Relay Therapeutics is currently under evaluation in gross profit category among its peers.
Relay Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Relay Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Relay Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Relay Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Relay Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -196 K | -205.8 K | |
| Net Interest Income | 31 M | 32.6 M | |
| Interest Income | 31 M | 32.6 M | |
| Operating Income | -373 M | -354.4 M | |
| Net Loss | -342 M | -324.9 M | |
| Income Before Tax | -342 M | -324.9 M | |
| Total Other Income Expense Net | 31 M | 32.6 M | |
| Net Loss | -261.5 M | -274.5 M | |
| Net Loss | -342 M | -324.9 M | |
| Income Tax Expense | -37.5 M | -35.6 M | |
| Non Operating Income Net Other | 10.1 M | 10.6 M | |
| Change To Netincome | 64.6 M | 67.8 M | |
| Net Loss | (2.79) | (2.93) | |
| Income Quality | 0.88 | 1.03 | |
| Net Income Per E B T | 0.79 | 0.81 |
Relay Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Relay Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Relay Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Relay Therapeutics' important profitability drivers and their relationship over time.
Use Relay Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Relay Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Relay Therapeutics will appreciate offsetting losses from the drop in the long position's value.Relay Therapeutics Pair Trading
Relay Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Relay Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Relay Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Relay Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Relay Therapeutics to buy it.
The correlation of Relay Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Relay Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Relay Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Relay Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Relay Therapeutics position
In addition to having Relay Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Disruptive Technologies Thematic Idea Now
Disruptive Technologies
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.